Oncology | Preclinical Developments

Nkarta Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Preclinical Oncology Biotech Nkarta Sets Terms for $150 million IPO

Lead Product(s): NKX101

Therapeutic Area: Oncology Product Name: NKX101

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Cowen

Deal Size: $150.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering July 02, 2020

Details:

Nkarta Therapeutics is working on off-the-shelf cancer therapies based on natural killer cells. The net proceeds will support the growth of company's pipeline.

Moleculin Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model

Lead Product(s): WP1066,Whole brain radiation therapy

Therapeutic Area: Oncology Product Name: WP1066

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

The article reported findings that Moleculin's STAT3 inhibitor, WP1066, used in combination with traditional whole brain radiation therapy resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors.

Simcha Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Simcha debuts with $25M to advance custom-built IL-18 for cancer

Lead Product(s): ST-067

Therapeutic Area: Oncology Product Name: ST-067

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: WuXi AppTec Inc.

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing June 24, 2020

Details:

Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.

ChemoCentryx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment

Lead Product(s): CCX559

Therapeutic Area: Oncology Product Name: CCX559

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

Study to be presented at American Association for Cancer Research meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent anti-tumor effects in animal models.

Simcha Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resistant IL-18 Cytokine

Lead Product(s): DR-18

Therapeutic Area: Oncology Product Name: DR-18

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

Oral presentation and poster detail DR-18’s ability to re-animate exhausted NK cells, bias differentiation of T cells toward highly active effectors and expand the population of critical immune cells inside the tumor microenvironment.

Enzo Biochem

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I

Lead Product(s): SK1-I

Therapeutic Area: Oncology Product Name: SK1-I

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2020

Details:

Enzo’s patent is directed to methods for treating hepatocellular carcinoma, the most common human liver cancer, using the company’s proprietary compound SK1-I and has a term extending into June 2038. Foreign patent applications in the same patent family are currently pending.

RubrYc Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

RubrYc Therapeutics To Present at AACR Virtual Conference

Lead Product(s): RTX-003

Therapeutic Area: Oncology Product Name: RTX-003

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2020

Details:

The company will present discovery and pre-clinical data from their lead program RTX-003, a CD25 targeted monoclonal antibody for selective depletion of regulatory T cells (Tregs) in the tumor microenvironment (TME) at the AACR Virtual Conference.

Tyme Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020

Lead Product(s): TYME-18

Therapeutic Area: Oncology Product Name: TYME-18

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2020

Details:

TYME’s CMBTs are proprietary investigational compounds that leverage cancer’s altered metabolism and associated vulnerabilities to specifically disrupt fundamental cellular processes.

BioInvent

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

Lead Product(s): BT-001

Therapeutic Area: Oncology Product Name: BT-001

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Transgene

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Cure rates exceeding 70% were seen in multiple mouse models, demonstrating the powerful therapeutic effect of BT-001 when used as a single agent, providing a solid basis for BT-001’s upcoming clinical development, with a phase I clinical trial expected to start in 2020.

Find

Find Novel Oncology Drugs in Preclinical Development

Preclinical

Product Type

Companies

Nkarta Therapeutics

Preclinical Oncology Biotech Nkarta Sets Terms for $150 million IPO

Moleculin Biotech

New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model

Simcha Therapeutics

Simcha debuts with $25M to advance custom-built IL-18 for cancer

ChemoCentryx

ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment

Simcha Therapeutics

Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resistant IL-18 Cytokine

Enzo Biochem

Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I

RubrYc Therapeutics

RubrYc Therapeutics To Present at AACR Virtual Conference

Tyme Technologies

TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020

BioInvent

BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models